In late July, shares of Curis and Summit Therapeutics surged following positive clinical trial results for oncology treatments. During the same period, Curium entered negotiations to acquire Lantheus Holdings in a deal initially valued at $7 billion. By August 3, Curium officially finalized an agreement to purchase the radiopharmaceutical company for a total value of up to $8 billion.
Curium enters definitive agreement to acquire Lantheus Holdings for up to $8 billion to consolidate its position in the radiopharmaceutical market.
Read the full storyCurium is reportedly in discussions to acquire Lantheus Holdings for approximately $7 billion, marking a major consolidation in the radiopharmaceutical sector.
Curis stock jumped 11% following positive data for emavusertib, while Summit Therapeutics rose on successful cancer treatment clinical trial results.